NCT06749795

LIV001 in Patients with Mild-to-Moderate Active Ulcerative Colitis (UC)

A Randomized, Double-Blind, Placebo Controlled, Multi -Center, Phase 1b Study to Evaluate the Safety and Tolerability of LIV001 in Patients with Mild-to-Moderate Active Ulcerative Colitis

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: Liveome Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

A Phase 1b study to evaluate the safety and tolerability of LIV001 in Patients with Mild-to- Moderate Active Ulcerative Colitis

Detailed description

A randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety and tolerability of LIV001 in patients with mild to moderate UC. Patients will receive LIV001 or placebo for 8 weeks. All patients will return to the site for a follow-up visit on week 12.

Conditions

• Ulcerative Colitis (UC)

Interventions

Type	Name	Description
DRUG	LIV001	Orally administered for 8 weeks
DRUG	Placebo	Orally administered for 8 weeks

Timeline

• Start date: 2025-03-24
• Primary completion: 2026-01-17
• Completion: 2026-03-24
• First posted: 2024-12-27
• Last updated: 2025-03-24

Locations

1 site across 1 country: Poland